Indinavir

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Calliditas Therapeutics to Present Nefecon Data at the ISN World Congress of Nephrology April 13 - 16 in Buenos Aires

Retrieved on: 
Monday, April 8, 2024
Diabetes, Anaphylaxis, IgA nephropathy, Glaucoma, CYP3A4, Dermatitis, Patient, Parasitism, Indinavir, Budesonide, Ritonavir, Quality of life, Peripheral edema, UPCR, Drug interaction, Vaccine, Saquinavir, Erythromycin, Congress, White, Risk, Headache, Spasm, Ketoconazole, Immunoglobulin A, Liver, Adrenal insufficiency, Immune system, Prediabetes, Proteinuria, Hypertension, Contraindication, Arthralgia, Ciclosporin, International Society, Immunosuppression, KOL, Acne, Infection, EGFR, Measles, Miscarriage, ISN, Hypersensitivity, Pregnancy, HPA, Chickenpox, Fetus, Birth, Itraconazole, CALT, Upper respiratory tract infection, Osteoporosis, Kidney, Cataract, Tropical ulcer, Pharmaceutical industry

The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.

Key Points: 
  • The ISN World Congress of Nephrology will be held in Buenos Aires, Argentina April 13-16, 2024.
  • Presentations will highlight the eGFR results found in patients on Nefecon as well as the data on quality of life during the trial.
  • There will also be a presentation on the subanalysis evaluating benefits of Nefecon for patients with lower levels of UPCR.
  • The congress will include a symposium, Evolving Landscape of eFGR and Proteinuria Surrogate Markers in IgA Nephropathy, moderated by KOL Richard Lafayette, M.D., F.A.C.P.

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Fungal infection, Medical Subject Headings, Marketing, European Commission, Liver, INN, Nitrate, Woman, Allergy, PDE5, Pelvic floor dysfunction, ATC, Hypotension, Itraconazole, International, Man, European, Headache, Ageing, Language, Blood, CGMP, Mouth, Eye, Pulmonary hypertension, Erectile dysfunction, Stroke, Kidney, Kidney disease, Angina, Ketoconazole, HIV, Ritonavir, Tablet, Indinavir, Select, Committee, Patient, Penis, Liver disease, Risk management, Anatomy, Medicine, Dialysis, IIA, Diabetes, CHMP, Medical device

Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Levitra, vardenafil, Date of authorisation: 06/03/2003, Revision: 33, Status: Authorised

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Urine, Liver, Medical Subject Headings, Fungal infection, Marketing, European Commission, INN, Stomach, Allergy, Itraconazole, Saquinavir, ATC, Glass, Nelfinavir, Depression, Kidney disease, Bleeding, International, European, Megacolon, Disease, Urinary retention, Language, Muscle weakness, Urinary bladder, Inflammation, Nefazodone, Water, Peanut, Ulcerative colitis, Colitis, Ketoconazole, Ritonavir, Tablet, Hyperkinesia, Indinavir, CYP3A4, Xerostomia, Select, Committee, Urination, Patient, Liver disease, Atazanavir, Anatomy, Medicine, Clarithromycin, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Toviaz, fesoterodine, Date of authorisation: 20/04/2007, Revision: 28, Status: Authorised

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 19, 2023
Kidney, Pregnancy, Adrenal insufficiency, Biomarker, EGFR, Vaccine, Glaucoma, Budesonide, American Society of Nephrology, Diabetes, Infection, Ritonavir, CYP3A4, Ciclosporin, Disease, Risk, Capsule, Itraconazole, UPCR, Parasitism, Hypersensitivity, Proteinuria, Alport syndrome, Saquinavir, Measles, Prediabetes, Miscarriage, Immune system, HPA, Ketoconazole, Fetus, CALT, Patient, Anaphylaxis, Tropical ulcer, IgA nephropathy, Indinavir, BAFF, Contraindication, Serum, Cataract, Birth, Administration, Society, Liver, Erythromycin, ASN, Hypertension, Osteoporosis, Immunoglobulin A, Drug interaction, Immunosuppression, Pharmaceutical industry, Dietary supplement, Alport

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.

Key Points: 
  • STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.
  • Poster presentation details are below and will be available on the Presentation and Publication page on the Calliditas' corporate website following the meeting.
  • It has not been established whether TARPEYO slows kidney function decline in patients with IgAN.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Calliditas Therapeutics to Present Seven Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023

Retrieved on: 
Thursday, October 19, 2023
Kidney, Pregnancy, Adrenal insufficiency, Biomarker, EGFR, Vaccine, Glaucoma, Budesonide, American Society of Nephrology, Diabetes, Infection, Ritonavir, CYP3A4, Ciclosporin, Disease, Risk, Capsule, Itraconazole, UPCR, Parasitism, Hypersensitivity, Proteinuria, Alport syndrome, Saquinavir, Measles, Prediabetes, Miscarriage, Immune system, HPA, Ketoconazole, Fetus, CALT, Patient, Anaphylaxis, Tropical ulcer, IgA nephropathy, Indinavir, BAFF, Contraindication, Serum, Cataract, Birth, Administration, Society, Liver, Erythromycin, ASN, Hypertension, Osteoporosis, Immunoglobulin A, Drug interaction, Immunosuppression, Pharmaceutical industry, Dietary supplement, Alport

STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.

Key Points: 
  • STOCKHOLM, Oct. 19, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) ("Calliditas"), today announced seven abstract presentations, including a late-breaking poster presentation, highlighting additional analyses of the Phase 3 NefIgArd study at the upcoming American Society of Nephrology (ASN) Kidney Week 2023 in Philadelphia, PA, November 1-5, 2023.
  • Poster presentation details are below and will be available on the Presentation and Publication page on the Calliditas' corporate website following the meeting.
  • It has not been established whether TARPEYO slows kidney function decline in patients with IgAN.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

Retrieved on: 
Friday, May 5, 2023
Hypersensitivity, Vaccine, Infection, Erythromycin, Glaucoma, Budesonide, Diabetes, European Renal Association, Osteoporosis, Fetus, Pregnancy, Hematuria, Parasitism, Cataract, HPA, Saquinavir, Immunoglobulin A, Liver, Tropical ulcer, CYP3A4, ERA, Measles, Hypertension, Proteinuria, Congress, Contraindication, Capsule, Indinavir, IgA nephropathy, Administration, Adrenal insufficiency, Patient, CALT, Risk, Anaphylaxis, Drug interaction, Immune system, Ketoconazole, Miscarriage, Ciclosporin, Ritonavir, Birth, Prediabetes, Immunosuppression, Itraconazole, UPCR, Disease, Pharmaceutical industry, Dietary supplement

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.

Key Points: 
  • STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.
  • "We are delighted that these data presentations have been selected for the upcoming ERA Congress 2023 and extend our congratulations to all the authors involved.
  • Poster presentation details are below and will be available on the Investor page on the Calliditas' corporate website following the meeting.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Calliditas Announces Late-Breaking Presentations at the 60th European Renal Association (ERA) Congress 2023

Retrieved on: 
Friday, May 5, 2023
Hypersensitivity, Vaccine, Infection, Erythromycin, Glaucoma, Budesonide, Diabetes, European Renal Association, Osteoporosis, Fetus, Pregnancy, Hematuria, Parasitism, Cataract, HPA, Saquinavir, Immunoglobulin A, Liver, Tropical ulcer, CYP3A4, ERA, Measles, Hypertension, Proteinuria, Congress, Contraindication, Capsule, Indinavir, IgA nephropathy, Administration, Adrenal insufficiency, Patient, CALT, Risk, Anaphylaxis, Drug interaction, Immune system, Ketoconazole, Miscarriage, Ciclosporin, Ritonavir, Birth, Prediabetes, Immunosuppression, Itraconazole, UPCR, Disease, Pharmaceutical industry, Dietary supplement

STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.

Key Points: 
  • STOCKHOLM, May 5, 2023 /PRNewswire/ -- Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) ("Calliditas") announced upcoming data presentations from the NeflgArd Phase 3 Study at the European Renal Association (ERA) Congress 2023.
  • "We are delighted that these data presentations have been selected for the upcoming ERA Congress 2023 and extend our congratulations to all the authors involved.
  • Poster presentation details are below and will be available on the Investor page on the Calliditas' corporate website following the meeting.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefits in a confirmatory clinical trial.

Calliditas Announces Publication of Cost-Effectiveness Analysis of Nefecon versus Best Supportive Care for People with IgA Nephropathy in the United States

Retrieved on: 
Tuesday, April 11, 2023
Hypersensitivity, Erythromycin, Kidney disease, Budesonide, Diabetes, Osteoporosis, Fetus, Pregnancy, Cataract, Dialysis, Contraindication, Capsule, Patient, CALT, Risk, Randomized controlled trial, Miscarriage, Ciclosporin, Disease, Outcomes research, Research, HPA, CYP3A4, Measles, Hypertension, Proteinuria, Administration, Anaphylaxis, Ketoconazole, ICER, Death, Indinavir, Itraconazole, Vaccine, EGFR, Parasitism, SOC, Liver, Tropical ulcer, QALY, Adrenal insufficiency, Standard of care, Drug interaction, Immune system, Infection, Glaucoma, Saquinavir, ClinicoEconomics and Outcomes Research, Ritonavir, Birth, Prediabetes, Immunosuppression, UPCR, Pharmaceutical industry, Dietary supplement, IgA nephropathy

NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) versus standard of care (SOC) for people with Primary IgA Nephropathy (IgAN) in the United States (US).

Key Points: 
  • NEW YORK, April 11, 2023 (GLOBE NEWSWIRE) -- Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”), announced the publication of a cost-effective analysis of Nefecon (marketed in the United States as TARPEYO® (budesonide) delayed release capsules) versus standard of care (SOC) for people with Primary IgA Nephropathy (IgAN) in the United States (US).
  • Health-state occupancy probabilities and key model inputs were based on the individual patient-level data from NefIgArd, the Phase 3 randomized controlled trial evaluating Nefecon.
  • Andrew Udell, president, North America at Calliditas stated: “These findings are timely and relevant in light of the 2-year eGFR results from the NefIgArd trial we recently announced.
  • Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory clinical trial.

Odyssey Therapeutics Appoints Darryl Patrick, D.V.M., Ph.D., as Executive Vice President of Non-Clinical Development

Retrieved on: 
Tuesday, May 24, 2022
Sigma Xi, Inflammation, United, Diplomate of National Board, Chemistry, Anatomical pathology, Disease, Pharmacology, Toxicology, Vertex Pharmaceuticals, Pathology, American College, Chemical safety assessment, Coronavirus Scientific Advisory Board (Turkey), Multimedia, Patient, View, Antibody, University of Health Sciences, Veterinary medicine, Therapy, Pharmacokinetics, Merck, Technology, Comparative medicine, Key, Diagnosis, Biotechnology, Uniformed Services University of the Health Sciences, Uniformed services, Autoimmune disease, University, Iowa State University, Michigan State University, LinkedIn, Protein, Outline of health sciences, LLC, Cancer, Drug discovery, Indinavir, Merck & Co., Pharmaceutical industry, Management, EU, Science, Odyssey, Vertex

BOSTON, May 24, 2022 /PRNewswire/ -- Odyssey Therapeutics, Inc. , a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today announced the appointment of Darryl Patrick, D.V.M., Ph.D., as Executive Vice President of Non-Clinical Development.

Key Points: 
  • BOSTON, May 24, 2022 /PRNewswire/ -- Odyssey Therapeutics, Inc. , a biotechnology company pioneering next generation precision immunomodulators and oncology medicines, today announced the appointment of Darryl Patrick, D.V.M., Ph.D., as Executive Vice President of Non-Clinical Development.
  • "I'm excited to welcome Darryl to accelerate the development pathway for transformative medicines and provide hope for patients in need."
  • Previously, Dr. Patrick held leadership roles at Vertex as Vice President, Non-Clinical Development, and Vice President, Exploratory Development, where he oversaw development candidates from discovery to approval and led global efforts spanning toxicology, drug metabolism and pharmacokinetics, and clinical pharmacology.
  • "Odyssey has assembled an exceptional team and is positioned to be a leader in precision medicines for inflammation and cancer," said Darryl Patrick, D.V.M., Ph.D., about his new role as Executive Vice President, Non-Clinical Development at Odyssey Therapeutics.